<code id='96C3C66C52'></code><style id='96C3C66C52'></style>
    • <acronym id='96C3C66C52'></acronym>
      <center id='96C3C66C52'><center id='96C3C66C52'><tfoot id='96C3C66C52'></tfoot></center><abbr id='96C3C66C52'><dir id='96C3C66C52'><tfoot id='96C3C66C52'></tfoot><noframes id='96C3C66C52'>

    • <optgroup id='96C3C66C52'><strike id='96C3C66C52'><sup id='96C3C66C52'></sup></strike><code id='96C3C66C52'></code></optgroup>
        1. <b id='96C3C66C52'><label id='96C3C66C52'><select id='96C3C66C52'><dt id='96C3C66C52'><span id='96C3C66C52'></span></dt></select></label></b><u id='96C3C66C52'></u>
          <i id='96C3C66C52'><strike id='96C3C66C52'><tt id='96C3C66C52'><pre id='96C3C66C52'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:53338
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain
          Pioneering cancer drug will cost $475,000. Analysts call it a bargain

          VictorSeguraIbarraandRitaSerda,Ph.D.,NCI,NIHTheFoodandDrugAdministrationonWednesdayapprovedafuturist

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

          DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par